Review of Retrospective Data
Demonstrates Importance of Superior Signal Quality and
First-in-Class Predictive Filter
COPENHAGEN, Denmark, May 14, 2024
/PRNewswire/ -- CathVision, a medical technology company
developing innovative electrophysiology solutions to enhance
clinical decision-making in the EP lab, will showcase a new
post-pulsed field ablation (PFA) residual energy calculation
method, as well as the AI-powered features of the ECGenius System™,
at Heart Rhythm 2024 in Boston,
May 16-19. Attendees can visit
CathVision at booth 457.¹
Published pivotal trials assessing PFA show that acute
techniques do not predict non-durable ablation. Despite the lack of
objective, in-procedure measurements of success, PFA is rapidly
being adopted as a treatment for atrial fibrillation.
CathVision has developed PFAnalyzer™, a method for calculating
residual energy in the tissue after PFA delivery that can help form
the basis of an objective, easy-to-use marker of success in
procedure.² The ECGenius System's unprecedented low-noise floor and
first-in-class Predictive Filter technology enable the energy
calculation technique. Data demonstrating the benefit of Predictive
Filter's exceptional noise reduction capabilities was recently
presented at EHRA 2024.
On May 15, at the Stanford
Biodesign New Arrhythmia Technologies Retreat, Dr. Suneet Mittal, chair of the Cardiovascular
Service Line for Valley Health System, will present an overview of
the ECGenius System, and demonstrate the concept of PFAnalyzer
highlighting the advantages of Predictive Filter.
"The field of EP is reassessing the importance of electrogram
signals in the context of PFA. Existing bipolar measurement
techniques do not tell an accurate story, so we are excited to have
found answers in our low-voltage unipolar electrograms," said
Mads Matthiesen, CEO of CathVision.
"The low noise and superior signal quality made possible by the
ECGenius System is uncovering tissue activity that is not evident
with other recording systems. This evidence demonstrates how
ECGenius System leverages the power of our CARDIALYTICS algorithms
to drive a paradigm shift that can further the advantages of
PFA."
The ECGenius System, CathVision's cutting-edge EP recording
technology and proprietary hardware amplifier, is designed to
acquire high-fidelity, low-noise cardiac electrograms. This
technology aids electrophysiologists in improving the diagnosis and
treatment of complex atrial arrhythmias, including atrial
fibrillation (AF). The system's data is then utilized by the
CARDIALYTICS suite of AI-based algorithms, which enable intelligent
electrogram interpretation and provide unprecedented levels of
automated analyses. These features are instrumental in helping
physicians measure the success of ablation outcomes for complex
atrial arrhythmias.
For more information about ECGenius System, CARDIALYTICS, or to
meet with CathVision at HRS 2024, please visit booth 457, contact
us here, and connect on LinkedIn.
About CathVision
CathVision is a medical technology
company that develops electrophysiology solutions centered around
an innovative EP recording system and AI-powered analytic tools.
Committed to empowering physicians to make more informed clinical
decisions in the EP lab, CathVision is redefining the necessity of
exceptional cardiac electrical signals to diagnose, characterize,
and treat the most common heart rhythm disorders. CathVision was
founded in 2013 and is headquartered in Denmark with a U.S. office in Minnesota.
Follow
CathVision: Twitter and LinkedIn
¹ ECGenius System is cleared for sale in the US. Not approved
for sale in the rest of the world.
² PFAnalyzer is not approved for sale.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cathvision-to-highlight-post-pfa-energy-calculation-measurement-method-at-hrs-2024-302145068.html
SOURCE CathVision